ABSTRACT
Carbonic anhydrase IX (CA IX) is a zinc-containing metalloenzyme that regulates cellular proliferation and acidbase balance. Its ability to transport carbon dioxide and maintain cellular homeostasis may play a key role in tumor progression, allowing tumor cells to adapt and survive even under hypoxic conditions. Interestingly, tumor cells cultured in hypoxic environments have been found to upregulate and express CA IX via the hypoxia-inducible factor 1 (HIF-1) pathway, further supporting the role of CA IX in tumor growth and spread. 1, 2 Carbonic anhydrase IX is a membrane isoenzyme and hence imparts a membrane-predominant staining pattern in immunohistochemistry. 2 Studies have shown that staining for CA IX is positive in 85% to 100% of clear cell renal cell carcinomas (CRCCs) and essentially negative in other renal cell carcinoma subtypes (eg, chromophobe renal cell carcinoma [ChRCC] ) and benign renal neoplasm (oncocytoma). [2] [3] [4] Upon completion of this activity you will be able to:
• describe the function of carbonic anhydrase (CA) IX in cell physiology and in neoplasms.
• summarize the diagnostic sensitivity and specificity of CA IX when evaluating a tumor of unknown origin.
• define an effective immunostaining panel to distinguish cholangiocarcinoma from primary hepatocellular carcinoma.
The ASCP is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The ASCP designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit ™ per article. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity qualifies as an American Board of Pathology Maintenance of Certification Part II Self-Assessment Module.
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This finding that CA IX is potentially a reliable and promising diagnostic marker for CRCC has laid the groundwork for additional studies to examine the extent of its diagnostic utility in other organs.
Hynninen et al 5 showed overexpression of CA IX in endometrial adenocarcinoma compared with normal endometrium. Although normal endometrium did stain focally for CA IX, the extent of staining in the malignant counterpart was higher. A few years ago, Donato et al 4 examined the expression of CA IX in tumors of the genitourinary tract and found increased CA IX reactivity in urothelial carcinomas, except those with plasmacytoid and signet ring cell patterns. Unlike these studies, expression of CA IX was more debatable with regard to gastric tumors, with some studies showing elevated expression and others not. [6] [7] [8] There are also very limited studies in the literature regarding CA IX expression in biliary tumors. Questions also arise about the reactivity of CA IX in normal renal epithelium. Most studies reported the absence of CA IX staining in normal kidney tissue, but a few have noted weak positive staining. 2, 4 Although some studies in the literature regarding the diagnostic utility of CA IX do sound promising, the sample size from which the conclusions were drawn is limited. In addition, the data on CA IX reactivity in certain tissue types and tumors are not entirely consistent. This study examines the expression of CA IX in various tumor types and normal tissues in the hope to shed more light on the utility of CA IX and clarify its level of expression.
Materials and Methods

Construction of Tissue Microarray Blocks
This study was approved by the institutional review board at Geisinger Medical Center (Danville, PA). A total of 1,551 cases from various organs (1, 
Results
CA IX Expression in Tumors
The details of the positive staining result for each case are listed in Table 1 (TMA) blocks with two punches of either 1.5 mm or 1.0 mm for each individual case were constructed. All cases were evaluated as TMA sections, except 18 cases of intrahepatic cholangiocarcinoma (ICC) and 17 cases of hepatocellular carcinoma (HCC), which were evaluated on routine sections.
Immunohistochemical Stains and Data Analysis
Immunohistochemical evaluation of the expression of CA IX (Cell Marque, Rocklin, CA; mouse monoclonal antibody, clone MRQ-54; 1:100 dilution; CCI mild retrieval) using TMA tissue sections was performed on 1,125 malignant tumors, 69 benign neoplasms, and 322 normal tissues. An additional 18 ICCs and 17 HCCs on routine sections were also included. This gives a cumulative total of 1,551 cases. The staining was done using the Ventana staining system (Ventana Medical Systems, Tucson, AZ) based on the previously published protocol. 9 Membranous staining was regarded as positive. The staining intensity was graded as weak or strong. The distribution of staining was recorded as negative (<5% of tumor cells stained), 1+ (5%-25%), 2+ (26%-50%), 3+ (51%-75%), or 4+ (>75%). The immunostained slides were further evaluated by two surgical pathologists (F.L. and H.L.). 
CA IX Expression in Normal Tissues
All normal intrahepatic bile ducts, stomach (gastric mucosa), and duodenum showed strong and diffuse (4+) positive staining for CA IX (100%). No staining was observed in normal liver (hepatocytes), kidney, lung, parotid gland, prostate, and seminal vesicle. Very focal (<5%) weak staining was seen in one case of normal kidney, and this was tabulated as negative since less than 5% of the cells stained. The results are summarized in Table 2 .
Discussion
There are approximately 15 isoenzymes of carbonic anhydrase. CA IX is of particular interest in that it has been found to have diagnostic, prognostic, and potentially therapeutic value. CA IX is a membrane-bound zinc metalloenzyme that plays a crucial role in cellular homeostasis, adhesion, and proliferation. It specifically catalyzes the reversible hydration of carbon dioxide (CO 2 + H 2 O → HCO 3 -+ H+) and, in doing so, allows cells to thrive even in states of hypoxia. Tumor cells that succumb to hypoxic conditions have been found to upregulate the expression of CA IX. As a transmembrane protein, CA IX is capable of facilitating the transport of extracellular CO 2 and maintaining intracellular pH homeostasis that is necessary for many biosynthetic processes. In the case of tumor cells, this may serve as a survival mechanism for tumor proliferation and spread. [1] [2] [3] It has been well documented that CA IX is overexpressed in CRCC. The literature has reported a diagnostic sensitivity ranging from 85% to 100%. [1] [2] [3] [4] Our study found that 90% of low-grade CRCCs (36/40) and 86% of high-grade CRCCs (32/37) showed overexpression of CA IX, with the vast majority exhibiting strong and diffuse membranous staining. Six (30%) of 20 papillary renal cell carcinomas (PRCCs) stained positively, which is consistent with the literature report of variable staining in this particular subtype. 4, 10 In this study, complete absence of staining was observed in ChRCCs and renal oncocytomas. These results further support the diagnostic utility of CA IX in distinguishing CRCC from ChRCC and oncocytoma. Together with other biomarkers such as CK7, CD117, RCC, and vimentin, this panel of antibodies has been proven to be useful in differentiating CRCC from ChRCC. 11 In general, CRCC is positive for CA IX, RCC, and vimentin, whereas ChRCC is positive for CK7 and CD117 and negative for CA IX, RCC, and vimentin. 11 Of note, variable expression of CA IX has been reported in uncommon renal tumors such as clear cell PRCC and Xp11 translocation-associated renal cell carcinoma. 10 Multilocular cystic renal cell carcinoma, a variant of CRCC, has also been found to show diffuse CA IX positivity. 12 As discussed below, CA IX is a highly sensitive but not entirely specific diagnostic immunomarker for clear cell RCC since carcinomas from other organs can express CA IX. However, it is worthwhile to emphasize here that CA IX expression in CRCC is usually diffusely and strongly positive. In this current study, 75% of positively stained CRCC cases demonstrated 4+ positivity (more than 75% of tumor cells stained); in contrast, none of the other types of the tumors, including endocervical adenocarcinoma and ICC, presented with this degree of diffuse staining in such a high percentage of the cases. A potential diagnostic pitfall that should be mentioned here is that CA IX can focally express in areas of tumor necrosis or immediately adjacent to the necrotic areas. Therefore, caution should be taken to avoid rendering this false-positive staining as "true positivity," especially in a small biopsy sample. This finding likely represents physiologic upregulation of HIF-1-a in these areas, which leads to CA IX overexpression. 13 Aside from renal tumors, studies have also examined the level of CA IX expression in other organs. Elevated CA IX reactivity has been reported in carcinomas of the uterine cervix but not to the degree that was seen in CRCC. 5 Our study also showed similar findings in TMA sections of endocervical adenocarcinomas. In addition, none of the prostate, thyroid, and low-grade breast carcinomas in our study showed staining for CA IX, which is in line with most other studies. 4, [14] [15] [16] [17] Studies on CA IX expression in biliary tumors are sparse. The level of CA IX expression in biliary lesions deserves some attention, since our study found that 90% of ICCs (26/29) stained positively for CA IX, with diffuse positivity in the majority. This is in contrast to the focal staining (1+) seen in 15% (5/34) of HCCs. These results suggest that CA IX may be useful in differentiating ICC from HCC, especially the pseudoglandular variant of HCC. When working on a challenging case, a panel of antibodies, including CA IX, MOC31, CD10, arginase 1, and glypican 3, can be helpful in the distinction of an HCC from a cholangiocarcinoma. 18, 19 Typically, a cholangiocarcinoma is positive for CA IX and MOC31 and negative for arginase 1, CD10, and glypican 3, whereas an HCC shows the reverse staining profile. 9 Since CA IX expression was observed in 58% of pancreatic adenocarcinomas, it has little value in distinguishing ICC from pancreatic adenocarcinoma. Normal bile ductal epithelium also showed strong diffuse membranous staining of CA IX. Saarnio and colleagues 20 also observed a similar percentage of CA IX reactivity in both intra-and extrahepatic cholangiocarcinomas compared with HCC. Although other immunohistochemical stains can be used to identify biliary tumors, CA IX may serve as an adjunctive tool when other stains are equivocal.
The utility of CA IX in differentiating CRCC from other tumors with clear cell features is also of great importance, especially in the context of metastatic lesions. Compared with CRCC, all clear cell carcinomas of the female gynecologic tract were negative in the study conducted by He et al. 21 However, our study found that 19% (5/27) of ovarian and uterine clear cell carcinomas were positive for CA IX, including two cases with diffuse positivity (3+). Therefore, caution should be taken when using CA IX in distinguishing CRCC from clear cell carcinoma of the ovary and uterus. As usual, a panel of markers, including CK7, CD10, CA IX, and RCC, can be considered. CRCC is usually positive for CA IX, RCC, and CD10 and negative for CK7, whereas the reverse is true for clear cell carcinoma of the ovary and uterus. Other markers such as von Hippel-Lindau tumor suppressor gene product (pVHL), paired box gene 8 (PAX-8), and hepatocyte nuclear factor 1b (HNF-1b) are not useful since they are frequently positive in both entities. 11 Estrogen receptor (ER) may not be particularly helpful since only a small percentage of clear cell carcinomas of the ovary and uterus are positive for ER. Different studies in the past have also reported the absence of CA IX reactivity in other tumors with clear cell features, such as thyroid neoplasms with clear cell change, seminomas with cytoplasmic clearing, and lobular breast carcinomas with vacuolated cytoplasm. 4, 14, 15 Our study also looked at the foamy gland variant of prostate adenocarcinoma, which at times can be difficult to distinguish from CRCC in limited samples, and found all cases to be negative for CA IX. These findings speak to the utility of CA IX in differentiating CRCC from other lesions with clear cell morphology and may be helpful in resolving metastatic clear cell tumors of unknown primary origin.
The expression of CA IX in normal tissues has been included in a number of studies. Of interest is the expression of CA IX in normal renal tubules, which can be difficult to distinguish from low-grade RCC in small tissue biopsy samples or fine-needle aspiration cytology specimens. Most studies have reported the absence of staining with CA IX, while few authors noted focal weak staining in normal renal tubular epithelium. 2, 4 This difference in staining result may be due to differences in antibodies, staining conditions, and staining platforms. Our study examined 20 cases of normal kidney on TMA sections and found the absence of staining in most cases, except one case that showed less than 5% of cells with minimal weak staining. This finding is consistent with that of the majority of other authors. 2, 4 The diagnostic use of CA IX has prompted multiple studies to examine its potential prognostic value and therapeutic implications. [22] [23] [24] Neumeister et al 15 reported that around one-fourth of triple-negative breast cancers (TNBCs) are associated with an elevated expression of CA IX and portend a worse overall survival compared with TNBCs without CA IX overexpression. High levels of CA IX have also been associated with shorter disease-free survival in patients with esophageal cancer, according to Birner and coworkers. 25 Similar findings were also reported in patients with oral squamous cell carcinoma. 26 These and other articles have led to studies that looked at the inhibition of CA IX as a potential therapeutic strategy. [27] [28] [29] [30] The two main treatment modalities that have been reported in the literature are the use of monoclonal antibodies and small-molecule inhibitors. 31 Small-molecule inhibitors of CA IX, such as sulfonamide-and coumarinbased inhibitors, have shown some ability in slowing cancer cell growth and reducing metastatic spread of malignant tumors. 32 Monoclonal antibodies have also been used in this regard. Given that CA IX contains an extracellular domain, it has been postulated that this will allow for easier access and direct binding of antibodies and potentially triggering antibody or receptor-mediated destruction of tumor cells. 8, 33 Additional studies on the inhibition of CA IX as a therapeutic target may shed more light in this area.
In summary, this study looked at the level of CA IX expression in a large numbers of various tumors and normal tissues, examined the diagnostic utility of CA IX in renal and nonrenal tumors, explored the role of CA IX in resolving metastatic tumors of unknown primary origin with clear cell morphology, and provided literature updates on the prognostic and therapeutic implications of CA IX. Our data (1) support and confirm that CA IX is of diagnostic utility in differentiating CRCC from ChRCC and oncocytoma; (2) provide evidence that CA IX can be used to distinguish low-grade CRCC from normal renal tubules, which can be challenging in small biopsy specimens or fine-needle aspirations; (3) suggest that CA IX may serve as an adjunctive immunohistochemical tool in separating cholangiocarcinomas from HCC; and (4) identify the role of CA IX as an important marker in separating CRCCs from other lesions with clear cell features (such as clear cell carcinoma of the ovary and uterus), especially in the context of metastatic tumors of unknown primary origin. We hope these findings provide more insight on the magnitude of the diagnostic utility of CA IX and substantiate its role as a valuable diagnostic marker. Additional studies on the molecular pathways and inherent components of CA IX may shed more light on and expand the clinical benefits of this marker.
